Abstracts tagged "Disease Activity"

Abstract Number: 2356 • 2013 ACR/ARHP Annual Meeting
Soluble Interleukin-2 Receptor Levels and The CD4/CD8 Ratio As Predictors Of The Efficacy Of Abatacept In Biologics-naïve Rheumatoid Arthritis Patients
Hajime Sano¹, Masahiro Sekiguchi¹, Masayasu Kitano¹, Naoto Azuma¹, Shinichiro Tsunoda¹, Kiyoshi Matsui¹ and Tsuyoshi Iwasaki², ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ²Department of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan
Background/Purpose: Abatacept (ABT) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells and thereby…
Abstract Number: 2083 • 2013 ACR/ARHP Annual Meeting
Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis
Gulnara Mamyrova¹, Lisa G. Rider², Olcay Jones³, Alison Ehrlich⁴, Lauren M. Pachman⁵, Robert Nickeson⁶, Lisa G. Criscione-Schreiber⁷, Frederick W. Miller², Lawrence K. Jung⁸ and James D. Katz¹, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ⁴Dermatology, The George Washington University, Washington, DC, ⁵Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Pediatrics, All Children's Hospital, St Petersburg, FL, ⁷Dept of Med/Rheum Div, Duke University School of Medicine, Durham, NC, ⁸Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: To assess environmental factors in relationship to increased disease activity (flare) in juvenile and adult dermatomyositis (DM). Methods: An online survey was conducted for…
Abstract Number: 1511 • 2013 ACR/ARHP Annual Meeting
What Impairs Balance In Ankylosing Spondylitis? Posture Or Disease Activity?
Osman Hakan Gunduz¹, Emel Ece Ozcan¹, Esra Giray¹ and Ilker Yagci², ¹Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey, ²Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: To compare ankylosing spondylitis (AS) patients and healthy individuals in terms of posture and balance and to identify the factors affecting balance among patients…
Abstract Number: 1301 • 2013 ACR/ARHP Annual Meeting
The Tumor Necrosis Factor Stimulated Gene-6 Promoter Reporter Can Monitor The Disease Activity In Rheumatoid Arthritis
Mathijs G.A. Broeren¹, Eline A. Vermeij¹, Onno J. Arntz², Miranda B. Bennink¹, Emma Sterken¹, Calin Popa², Tim L. Jansen³, Wim B. van den Berg⁴ and Fons A.J. Van de Loo⁵, ¹Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Radboud UMC, Nijmegen, Netherlands, ⁴Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: An important step in the optimal personalized treatment of rheumatoid arthritis (RA) patients, is the accurate assessment of disease activity, disease progression and therapy…
Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting
Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Melissa E. Munroe¹, Jourdan R. Anderson², Krista M. Bean³, Joan T. Merrill⁴, Joel M. Guthridge³, Virginia C. Roberts³, Linda F. Thompson^5,6 and Judith A. James^4,7, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…
Abstract Number: 2811 • 2013 ACR/ARHP Annual Meeting
Disease Characteristics and Treatment Patterns In US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection
Ruchika Patel¹ and Joshua Baker², ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C (HCV) is estimated at 0.02%, affecting around 40,000 Americans. To our knowledge, no existing…
Abstract Number: 2341 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Adalimumab Plus Methotrexate Therapy In Rheumatoid Arthritis Non-Responders Receiving Methotrexate Monotherapy Or Adalimumab Combination Therapy: Results From The Optima Trial
Josef S. Smolen¹, Ronald F. van Vollenhoven², Roy Fleischmann³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Anabela Cardoso⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Leeds Teaching Hospital, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie, Amadora, Portugal, ⁸AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁹University of California, San Diego, La Jolla, CA
Background/Purpose: EULAR recommendations advocate Methotrexate (MTX) as first line therapy. For patients (pts) who fail to attain remission or low disease activity (LDA) after 6…
Abstract Number: 1930 • 2013 ACR/ARHP Annual Meeting
Patients’ Response To a Sleep Question and Disease Activity In Multiple Rheumatic Conditions
Sapna Sangani¹ and Martin J. Bergman², ¹Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ²Medicine, Drexel University College of Medicine, Philadelphia, PA
Patient's Response To A Sleep Question And Disease Activity Levels In Multiple Rheumatic ConditionsBackground/Purpose: Sleep disturbances can have an impact on the quality of life…
Abstract Number: 1519 • 2013 ACR/ARHP Annual Meeting
Meeting The ACR 2010 Fibromyalgia Criteria Worsens Disease Activity and Quality Of Life In Patients With Axial Spondyloarthritis Treated With Infliximab
Mathieu Verdet¹, Clément Guillou², Julien Michaud¹, Christopher Banse¹, Sandra Desouches¹, Gilles Avenel³, Quentin Bréhier⁴, Aurélia Bisson-Vaivre¹, Sophie Pouplin¹ and Olivier Vittecoq⁵, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ³Rheumaotlogy, Rouen University Hospital, Rouen, France, ⁴Rheumatology, Le Havre Hospital, Le Havre, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Managing axial spondyloarthritis (aSpA) may be difficult because sometimes patients are not good responder to anti-TNF. We made the hypothesis that in certain patients,…
Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting
Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries
Dimitrios A. Pappas¹, Kathy Lampl², Joel M. Kremer³, Sebastião C. Radominski⁴, Janos Gal⁵, Fredrik Nyberg⁶, Anand N. Malaviya⁷, Aimée Whitworth⁸, Oscar Luis Rillo⁹, Allan Gibofsky¹⁰, Tatiana Popkova¹¹, Meilien Ho¹², Ieda Laurindo¹³, George W. Reed⁸, Eduardo Mario Kerzberg¹⁴, Laura Horne¹⁵, Roman Záhora¹⁶, Katherine C. Saunders¹⁷, Bernado Pons-Estel¹⁸, Alina U. Onofrei¹⁹ and Jeffrey D. Greenberg²⁰, ¹Columbia University, New York, NY, ²AstraZeneca R&D Wilmington, Wilmington, DE, ³Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Universidade Federal do Paraná, Curitiba, Brazil, ⁵Rheumatology, County Hospital, Kecskemet, Hungary, ⁶AstraZeneca R&D, Mölndal, Sweden, ⁷Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, ⁸CORRONA, Inc., Southborough, MA, ⁹Hospital Tornú, Capital Federal, Argentina, ¹⁰Medicine and Public Health, Hospital for Special Surgery, New York, NY, ¹¹Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, ¹²AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹³Rheumatology, Universidade de São Paulo, São Paulo, Brazil, ¹⁴Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, ¹⁵AstraZeneca, Wilmington, DE, ¹⁶Revmatologická ambulance, Terezin, Czech Republic, ¹⁷Corrona, LLC., Southborough, MA, ¹⁸Hospital Provincial de Rosario, Rosario, Argentina, ¹⁹University of Massachusetts Medical School, Worcester, MA, ²⁰Rheumatology, NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data. We explored variations in…
Abstract Number: 522 • 2013 ACR/ARHP Annual Meeting
Abatacept Reduces Disease Activity In Early Primary Sjögren’s Syndrome:One Year Results From a Phase II Open-Label Study
PM Meiners¹, A Vissink², Fkl Spijkervet³, EA Haacke⁴, WH Abdulahad⁵, E Brouwer⁵, MG Huitema⁵, N Sillevis Smitt-Kamminga⁶, FGM Kroese⁷, S Arends⁵ and H Bootsma⁵, ¹Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, Netherlands, ⁴Pathology, University Medical Center Groningen, Groningen, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Opthalmology, University Medical Center Groningen, Groningen, Netherlands, ⁷Rheumatology and clinical immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Traditional DMARDs have limited effects in primary Sjögren's (pSS) patients. B cell depletion therapy with rituximab showed efficacy, but had some side-effects. T and…
Abstract Number: 2781 • 2013 ACR/ARHP Annual Meeting
The Disease Characteristics and Predictors Of Minimal Disease Activity On TNF Blockers- Results From A Longitudainal Observational Cohort
Amir Haddad¹, Arane Thavaneswaran¹, Ioana Ruiz Arruza², Vinod Chandran², Richard J. Cook³ and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: A state of Minimal Disease Activity (MDA) has been defined and validated as a target for treatment in PsA. The purpose of the study…
Abstract Number: 2305 • 2013 ACR/ARHP Annual Meeting
Influence Of Disease Activity On The Physical Activity Of Rheumatoid Arthritis Patients
Vanesa Hernández-Hernández¹, Ivan Ferraz-Amaro², Esmeralda Delgado-Frías¹, Sagrario Bustabad-Reyes¹ and Federico Diaz-Gonzalez³, ¹Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology, Servicio de Reumatologia. Hospital Universitario de Canarias, Tenerife, Spain, ³Rheumatology, Servicio de Reumatologia.Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: It is generally assumed that rheumatoid arthritis (RA) patients tend to exercise less than what is currently recommended. However, there is little data on…
Abstract Number: 1947 • 2013 ACR/ARHP Annual Meeting
The 7-Joint Ultrasound Score Is a Feasible Tool For Evaluating Joint Inflammation In Rheumatoid Arthritis Patients. Experience Among Rheumatologists With Basic Or Intermediate Level Of Ultrasound Training
Jana Hurnakova^1,2, Jakub Zavada^2,3, Herman F. Mann^1,2, Ladislav Senolt^2,4, Martin Klein^2,4, Petra Hanova^5,6, Sarka Forejtova^2,4, Marta Olejarova^2,4, Olga Ruzickova^2,4, Olga Sleglova^2,4 and Karel Pavelka^2,7, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ²1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Prague, Prague, Czech Republic, ⁵Institute of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁶1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
Background/Purpose: Musculoskeletal ultrasound plays an increasingly important role in monitoring disease activity and therapy response. German US-7 score is a recently introduced ultrasound scoring index…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].